Travere Therapeutics, Inc.
TVTX
$33.99
-$1.20-3.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 44.05% | 40.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 44.05% | 40.03% | |||
| Cost of Revenue | 5.09% | -1.33% | |||
| Gross Profit | 75.23% | 110.73% | |||
| SG&A Expenses | 13.43% | 4.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.09% | 2.16% | |||
| Operating Income | 297.08% | 70.36% | |||
| Income Before Tax | 301.92% | 69.08% | |||
| Income Tax Expenses | -60.00% | -48.72% | |||
| Earnings from Continuing Operations | 301.54% | 69.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 301.54% | 69.06% | |||
| EBIT | 297.08% | 70.36% | |||
| EBITDA | 2,880.89% | 104.57% | |||
| EPS Basic | 300.91% | 69.27% | |||
| Normalized Basic EPS | 301.23% | 69.28% | |||
| EPS Diluted | 292.05% | 69.27% | |||
| Normalized Diluted EPS | 274.97% | 69.28% | |||
| Average Basic Shares Outstanding | 0.32% | 0.67% | |||
| Average Diluted Shares Outstanding | 15.37% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||